BioLineRx - ADR Peer Comparison

$2.69

$-0.08 (-2.72%)

As on 28-Aug-2026 13:33EDT

Market cap

$12 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

--

P/B Ratio

0.8

Div. Yield

0 %

Edit

	BioLineRx - ADR	Zai Lab - ADR	Galapagos NV - ADR	DBV Technologies S.A. - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Market cap ($ Mln)	12	2,920	1,862	914	839
Revenue ($ Mln)	1	450	1,044	--	366
Net Profit ($ Mln)	-8.89	-188.21	488.78	-175.85	9.27
Net Margin (%)	-633.66	-41.86	46.83	--	2.53
RoE (%)	-43.66	-28.46	15.95	-106.84	3.39
Price to Earnings	--	--	3.18	--	84.64
Price-To-Book	0.76	4.82	0.49	5.59	3.06

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	BioLineRx - ADR	Zai Lab - ADR	Galapagos NV - ADR	DBV Technologies S.A. - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Operating Revenue	1.40	449.61	1,043.75	0.00	366.45
Cost of Revenue	0.35	195.71	20.81	12.78	49.36
Gross Profit	0.43	269.08	1,082.51	-17.67	330.63
Operating Expenses	11.97	517.90	631.30	176.86	304.74
Operating Profit (EBIT)	-10.92	-264.00	391.64	-181.14	12.35
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-9.75	-190.72	471.19	-178.93	15.84
Provision for Tax	0.00	-2.51	-16.74	-3.09	6.57
Profit after Tax (Net Income)	-8.89	-188.21	488.78	-175.85	9.27
Minority Interest	0.99	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	BioLineRx - ADR	Zai Lab - ADR	Galapagos NV - ADR	DBV Technologies S.A. - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Shareholder's Funds	16.67	607.04	3,253.37	160.40	270.49
Minority Interest	0.99	0.00	0.00	0.00	0.00
Non-Current Liabilities	4.34	39.17	18.64	8.50	104.25
Current Liabilities	13.62	428.58	100.42	54.30	93.25
Total Liabilities	40.90	1,172.38	3,405.07	233.72	499.81

Assets ($ Mln)

	BioLineRx - ADR	Zai Lab - ADR	Galapagos NV - ADR	DBV Technologies S.A. - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Non-Current Assets	17.22	160.76	311.69	21.30	187.30
Current Assets	21.58	914.04	3,060.74	201.90	280.69
Total Assets	40.90	1,172.38	3,405.07	233.72	499.81
Total Debt*	9.07	254.58	6.44	21.00	113.30
Net Current Assets	7.96	485.45	2,960.31	147.60	187.44

Cashflow ($ Mln)

	BioLineRx - ADR	Zai Lab - ADR	Galapagos NV - ADR	DBV Technologies S.A. - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Cash From Operating Activities	-8.14	-150.79	-189.23	-121.18	54.71
Cash Flow from Investing Activities	-8.61	307.87	219.35	-1.37	26.25
Cash from Financing Activities	8.95	72.35	-3.14	276.18	1.50
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	BioLineRx - ADR	Zai Lab - ADR	Galapagos NV - ADR	DBV Technologies S.A. - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
ROCE (%)	-4.17	-18.15	10.44	-130.25	0.77
ROE (%)	-43.66	-28.46	15.95	-106.84	3.39
ROA (%)	-16.17	-12.55	12.32	-74.77	1.69
EBIT Margin (%)	-615.96	-41.09	-18.97	--	8.34
Net Margin (%)	-633.66	-41.86	46.83	--	2.53
Cash Profit Margin (%)	0.00	0.00	--	--	0.00

Growth Ratios

	BioLineRx - ADR	Zai Lab - ADR	Galapagos NV - ADR	DBV Technologies S.A. - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Revenue Growth (%)	-93.72	5.10	262.17	-1.00	-99.61
EBIT Growth (%)	-267.28	11.36	-70.17	-45.21	523.06
Net Profit Growth (%)	-161.67	11.44	388.30	-43.04	-99.68
EPS Growth (%)	-26.17	-1.87	387.50	7.30	-96.78
Book Value Growth (%)	-64.01	-25.05	18.33	108.85	7.71

Valuation Ratios

	BioLineRx - ADR	Zai Lab - ADR	Galapagos NV - ADR	DBV Technologies S.A. - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Price / Earnings	-10.18	-11.11	6.71	-9.99	469.58
Price / Book Value	0.66	2.73	0.67	8.70	4.83
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-5.91	-9.39	-2.33	-9.30	36.65
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	BioLineRx - ADR	Zai Lab - ADR	Galapagos NV - ADR	DBV Technologies S.A. - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Debt to Equity	0.20	0.00	0.00	0.00	0.34
Short term debt to equity ratio	0.28	0.40	0.00	0.09	0.03
Current Ratio	1.58	2.13	30.48	3.72	3.01
Quick Ratio	1.43	1.92	30.30	3.72	2.31
Interest Coverage	-7.77	-30.87	20.36	--	2.08

Operating Efficiency Ratios

	BioLineRx - ADR	Zai Lab - ADR	Galapagos NV - ADR	DBV Technologies S.A. - ADR	Pharming Group N.V. ADS each representing 10 (PHAR)
Debtors to sales (%)	134.76	16.23	5.18	--	15.55
Asset Turnover	0.03	0.30	0.26	0.00	0.67
Receivable days	663.18	77.60	16.53	--	51.78
Inventory Days	1,273.60	109.55	452.54	--	492.02
Payable days	2,183.86	231.78	1,242.94	650.68	466.91
Cash Conversion Cycle	-247.09	-44.63	-773.87	--	76.89

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly